Predictor Value of PD-L1 for Radiotherapy Response in Locally Advanced Non-Small Cell Lung Cancer

DEMİRCAN N. V., ACAR E., ŞENTÜRK M. E., GÜZEL Ç., EROĞLU ARKOÇ N., AKYÜREK N., ...Daha Fazla

TURK ONKOLOJI DERGISI, cilt.37, sa.3, ss.227-238, 2022 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 37 Sayı: 3
  • Basım Tarihi: 2022
  • Doi Numarası: 10.5505/tjo.2022.3523
  • Dergi Adı: TURK ONKOLOJI DERGISI
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CINAHL, EMBASE, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.227-238
  • Gazi Üniversitesi Adresli: Evet

Özet

The discovery of PD-L1 receptors triggered a great interest in immunotherapeutics for the management of locally advanced non-small-cell lung cancer (NSCLC). The efficacy of immunotherapeutics for overall survival (OS) in locally advanced NSCLC has been proven in several clinical trials. However, no data exist for the relationship between radiotherapy (RT) response and programmed death-ligand (PD-L1) receptor positivity in the literature. In this regard, we aimed to investigate the predictor value of PD-L1 receptors for RT response. METHODS Eighty patients who were diagnosed as having locally advanced NSCLC were selected from among patients in whom PD-L1 status was assessed in the Gazi University pathology laboratory. The relationship between PD-L1 and progression-free survival (PFS), OS, metastasis-free survival (MFS), RT response, and RT doses was evaluated using Kaplan-Meier and Cox regression analysis. Chi-square and t-tests were used for descriptive statistics. RESULTS The median follow-up was 16.1 months. The mean age was 61.1 years. PD-L1 positivity was detected in 34 patients. One year and 2-year OS and PFS ratios were found as 87%, 54% and 65%, 30%, respectively. The median OS and PFS were 26.8 and 15.1 months, respectively. There was no statistically significant difference between PD-L1 receptor status and OS and PFS (p=0.736 and p=0.372, respectively). In the PD-L1 positive subgroup analysis for OS, doses higher than 60 Gy (n=28, mean dose 64.6±1.53) were found superior to the 60 Gy dose (n=6) (p=0.034). The median MFS was 33 months. CONCLUSION PD-L1 status did not seem to be a predictor for RT response. However, despite the low number of patients in the 60 Gy group, our study showed that dose-escalation could improve survival in PD-L1 positive locally advanced NSCLC.